Tools for advocacy and communications to increase contraceptive access and options

DMPA-SC is transforming contraceptive access, use, and choice for women and adolescent girls. Advocates play an important role in making sure their country’s policies and funding support access to a broad method mix, including options like DMPA-SC and self-injection.

The Injectable Access Collaborative’s DMPA-SC Advocacy Pack is designed to accelerate your advocacy efforts. It consists of evidence-based materials for advocates to use both for their own strategy development and for direct advocacy with decision-makers. Available in English and French in PDF, Word, and PowerPoint formats, materials are customizable and unbranded so that you can tailor them to your country context. Advocacy Pack for Subcutaneous DMPA. Product brand name Sayana Press.

This DMPA-SC Advocacy Pack brief offers concise, evidence-based information to help answer common questions and dispel myths about injectable contraception.

This DMPA-SC Advocacy Pack brief details the strong body of evidence and experience with self-injection of DMPA-SC, including how the practice can reduce access-related barriers, improve contraceptive continuation, and enhance women’s autonomy.

These DMPA-SC Advocacy Pack briefs outline existing evidence on DMPA-SC grouped into top-line messages featuring data from different countries. Several “spotlight” handouts on specific topics can be paired with the summary brief as needed. All handouts can be printed and distributed directly to decision-makers.

This DMPA-SC Advocacy Pack brief summarizes recent evidence from African countries on the costs and cost-effectiveness of DMPA-SC. Key findings include that DMPA-SC may help reduce service delivery costs by catalyzing expansion of channels closest to women and that self-injected DMPA-SC is cost-saving as compared to clinic-administered DMPA-IM when accounting for costs to women and health systems.

The G-FINDER project tracks annual investment in research and development for new products and technologies that are designed to address the persistent global health challenges that disproportionately affect the world’s most disadvantaged people. The project’s goal is to provide funders, policy makers, researchers, advocates, journalists and others with an accurate understanding of the research and development funding landscape for neglected diseases and other global health priorities. The G-FINDER data portal provides open access to all of the underlying data captured by the G-FINDER survey every year since 2007.

The Track20 Project, implemented by Avenir Health, monitors progress towards achieving the goals of the global FP2020 initiative, adding an additional 120 million modern method users between 2012 and 2020 in the world’s 69 poorest countries. Track20 works directly with governments in participating FP2020 countries to collect, analyze and use data to monitor progress annually in family planning and to actively use data to improve family planning strategies and plans. Track20 activities and efforts are focused on countries that chose to make a commitment to the FP2020 global initiative, referred to as Track20 Focus Countries. The remaining FP2020 countries, referred to as Additional Track20 Countries, will also receive some technical support.

The Contraceptive Technology Innovation (CTI) Exchange is a platform for increasing global access to resources on contraceptive research, development, registration, and introduction through collaboration and knowledge sharing. The site features Calliope, the Contraceptive Pipeline Database, which provides information on new and future contraceptive products, including long-acting and novel products currently only available in limited markets.

This website portal serves as a repository for full-text articles about all aspects of international drug and health product registration.

This brief lists key references and resources from the evidence base on DMPA-SC. Pair this with the Evidence at-a-glance brief if your target decision-maker would like to have access to the data in that handout.